PLENARY KEYNOTE SESSIONS
TUESDAY, JUNE 15
11:45 am PD-1 Antibodies Are Transforming Cancer Treatment as Precision Medicine Informed Mono- or Combination Therapy
Roy Baynes, MD, PhD, Senior Vice President & Head, Global Clinical Development, CMO, Merck Research Laboratories
Precision medicine tools have enabled PD-1 antibody therapy to transform cancer care in a number of major tumor types.
They have also provided insights to resistance biology and potential logical choices for combination therapies. Combination therapies with PD-1 antibodies as foundational are beginning to impact many therapeutic choices.
12:05 pm Sponsored Presentation (Opportunity Available)
12:15 Precision Medicine Strategies: The Next Level
Holly Soares, PhD, Vice President & Head, Precision Medicine, Pfizer, Inc.
Recent
advances and impact of precision medicine strategies in drug development will be reviewed. Technology advances using more spatially and cellularly precise high dimensional profiling will be addressed along with a few novel case studies of patient
selection and mechanism-of-action biomarkers.
12:35 Keynote Panel Discussion: Implementing Precision Medicine at Big Pharma
Moderator:
Roy Baynes, MD, PhD, Senior Vice President & Head, Global Clinical Development, CMO, Merck Research Laboratories
Panelists:
Holly Soares, PhD, Vice President & Head, Precision Medicine, Pfizer, Inc.
Elizabeth B. Somers, Senior Director, Diagnostic Pathway Lead, Alzheimer's Disease Franchise, Eisai, Inc.
Zhen Su, MD, MBA, Senior Vice President, Head of Global Oncology Franchise, EMD Serono, a business of Merck KGaA, Darmstadt, Germany
WEDNESDAY, JUNE 16
12:10 pm AstraZeneca R&D: Turning Science into Medicine
Mene N. Pangalos, PhD, Executive Vice President, Biopharmaceuticals R&D, AstraZeneca
12:30 Sponsored Presentation (Opportunity Available)
12:40 Reimagining Global Health through Artificial Intelligence: The Roadmap to AI Maturity
Ann Aerts, MD, Head, Novartis Foundation
4:15 Keynote Panel Discussion: Women in Science
Moderator:
Razelle Kurzrock, MD, CMO, Chair, Clinical Trials Committee, Worldwide Innovative Network (WIN) for Personalized Cancer Therapy
Panelists:
Emilee Connors, PhD, Scientific Director, Medical Affairs, Merck Research Labs
Lauren Leiman, Executive Director, BloodPAC
Holly Soares, PhD, Vice President & Head, Precision Medicine, Pfizer, Inc.
Theresa L. Whiteside, PhD, Professor, Pathology, Immunology & Otolaryngology, University of Pittsburgh
THURSDAY, JUNE 17
12:25 pm Innovation in Drug Discovery
Stephen Rees, Vice President, Discovery Biology, AstraZeneca
12:45 Sponsored Presentation (Opportunity Available)
12:55 Keynote Panel Discussion: Innovation for Pharma R&D Productivity and Efficiency
Moderator:
Cecilia Schott, PharmD, MBA, Head, Global Precision Medicine Strategy, Oncology Business Unit, Novartis
Panelists:
Jason Ekert, PhD, Senior Director & Head, Complex In Vitro Models, GlaxoSmithKline
Michael Jackson, PhD, Senior Vice President, Drug Discovery and Development, Conrad Prebys Center for Chemical Genomics, Sanford Burnham Prebys Medical Discovery Institute
Emmett Schmidt, MD, PhD, Vice President, External Collaborations, Oncology Early Development, Merck